WHO Approves First Malaria Vaccine

Malaria is exceedingly rare in the United States and other developed nations, but it remains a crucial problem in sub-Saharan Africa. A new vaccine called Mosquirix created by GlaxoSmithKline has the potential to be a serious game-changer for millions of people affected by the parasitic illness spread by mosquitoes. About 260,000 children under the age of 5 perish from the disease each year, but the groundbreaking vaccine could save many of those children’s lives

Download your free digital edition of Radiant at radianthealthmag.com/free.